SPS
ELVN icon

Susquehanna Portfolio Strategies’s Enliven Therapeutics ELVN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Sell
14,462
-34,599
-71% -$1.47M 0.01% 611
2026
Q1 		$1.92M Buy
49,061
+320
+0.7% +$8.87K 0.03% 502
2025
Q4 		$751K Buy
48,741
+17,002
+54% +$339K 0.01% 693
2025
Q3 		$650K Sell
31,739
-35,941
-53% -$725K 0.01% 765
2025
Q2 		$1.36M Buy
+67,680
New +$1.28M 0.03% 454

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Susquehanna Portfolio Strategies's ELVN Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its Enliven Therapeutics (ELVN) stake by 71% in Q2 2026, selling an estimated $1.47M and leaving 14,462 shares worth $734K. The position accounts for 0.01% of the portfolio, ranked #611.

Susquehanna Portfolio Strategies first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.92M in Q1 2026. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Susquehanna Portfolio Strategies held 14,462 shares of Enliven Therapeutics worth $734K as of Q2 2026.
  • Susquehanna Portfolio Strategies sold 34,599 Enliven Therapeutics shares in Q2 2026, an estimated $1.47M.
  • Enliven Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #611 holding.
  • Susquehanna Portfolio Strategies first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Susquehanna Portfolio Strategies's Enliven Therapeutics position peaked at $1.92M in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.